Nan Fung Group Holdings Ltd

Q2 2023 13F Combination Report, Stock Holdings

Signature - Title
Tang Chun Wai Nelson - Director
Location
Kai Tak, Hong Kong
Holdings as of
June 30, 2023
Value $
$156M
Num holdings
43
Date filed
8/11/2023, 04:14 PM
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q1 2023 - May 12, 2023
Next filing
Q3 2023 - Nov 13, 2023
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2023 Q2 compared to 2023 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Tang Chun Wai Nelson Director Central, Hong Kong 8/11/2023

List of Other Managers Reporting for Nan Fung Group Holdings Ltd:

Name Holdings Value Location File Number
Pivotal bioVenture Partners Investment Advisor LLC $168M San Francisco, CA 028-20630
Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631

Other Included Managers (2):

Num Name Location File Number
1 Pivotal bioVenture Partners Investment Advisor LLC San Francisco, CA 028-20630
2 Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631